Vaccination: role in metastatic melanoma. (Q36573868)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Vaccination: role in metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Licia Rivoltini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Lorenzo Pilla

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Roberta Valenti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Andrea Marrari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Roberto Patuzzo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Giorgio Parmiani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

1305-1318

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16925496%20AND%20SRC:MED&resulttype=core&format=json

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Skin cancers after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

M-Vax: an autologous, hapten-modified vaccine for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Vaccination of patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Vaccines for melanoma: translating basic immunology into new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Diversity and recognition efficiency of T cell responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Innate immunity: impact on the adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Universal tumor antigens as targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

DNA vaccines: immunology, application, and optimization*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Heat shock proteins and their use as anticancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Working with NKT cells--pitfalls and practicalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1305